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Abstract
Background: Whether PR prolongation independently predicts new-onset ischemic events of myocardial infarction
and stroke was unclear. Underlying pathophysiological mechanisms of PR prolongation leading to adverse cardiovascular
events were poorly understood. We investigated the role of PR prolongation in pathophysiologically-related adverse
cardiovascular events and underlying mechanisms.
Methods: We prospectively investigated 597 high-risk cardiovascular outpatients (mean age 66 ± 11 yrs.; male
67%; coronary disease 55%, stroke 22%, diabetes 52%) for new-onset ischemic stroke, myocardial infarction
(MI), congestive heart failure (CHF), and cardiovascular death. Vascular phenotype was determined by carotid
intima-media thickness (IMT).
Results: PR prolongation >200 ms was present in 79 patients (13%) at baseline. PR prolongation >200 ms was associated
with significantly higher mean carotid IMT (1.05 ± 0.37 mm vs 0.94 ± 0.28 mm, P = 0.010). After mean study
period of 63 ± 11 months, increased PR interval significantly predicted new-onset ischemic stroke (P = 0.006),
CHF (P = 0.040), cardiovascular death (P < 0.001), and combined cardiovascular endpoints (P < 0.001) at cut-off >200 ms.
Using multivariable Cox regression, PR prolongation >200 ms independently predicted new-onset ischemic stroke
(HR 8.6, 95% CI: 1.9–37.8, P = 0.005), cardiovascular death (HR 14.1, 95% CI: 3.8–51.4, P < 0.001) and combined cardiovascular
endpoints (HR 2.4, 95% CI: 1.30–4.43, P = 0.005). PR interval predicts new-onset MI at the exploratory cut-off >162 ms (C-
statistic 0.70, P = 0.001; HR: 8.0, 95% CI: 1.65–38.85, P = 0.010).
Conclusions: PR prolongation strongly predicts new-onset ischemic stroke, MI, cardiovascular death, and combined
cardiovascular endpoint including CHF in coronary patients or risk equivalent. Adverse vascular function may implicate
an intermediate pathophysiological phenotype or mediating mechanism.
Keywords: PR interval prolongation, Cardiovascular death, Myocardial infarction, Ischemic stroke, Carotid intima-media
thickness, Vascular function, Pathophysiological mechanism
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Background
First-degree heart block, referred to as prolongation of
PR interval beyond >200 ms on the electrocardiogram
(ECG), has long been considered a benign functional
variation [1]. Nevertheless, recent major studies including
the ARIC [2] and Framingham Heart Study [3], re-ignited
controversies over the pathological nature of PR prolonga-
tion by consistently demonstrating that PR prolongation
was linked to risk of atrial fibrillation in the population. In
the Framingham study, PR prolongation was further asso-
ciated with increased risk of pacemaker implantation and
all-cause death [3]. Nevertheless, the roles of PR prolonga-
tion in atherosclerotic cardiovascular (CV) disease, as well
as outcome prediction in CV patients under clinical
care, remained largely unknown. The Heart and Soul
Study showed that PR prolongation predicted heart failure
hospitalization and CV mortality in patients with stable
coronary artery disease (CAD) [4]. We further showed that
PR prolongation when incorporated into the CHADS2 and
CHA2DS2-VASc scores, augments their predictive power
for new-onset CV events [5]. Nevertheless, the individual
role of PR prolongation, a precursor to atrial fibrillation, for
new-onset ischemic events of stroke and myocardial infarc-
tion was not clearly established. Importantly, underlying
pathophysiological mechanistic basis of how PR prolonga-
tion may lead to adverse CV outcomes remained also
poorly understood.
In a prior study of 88 healthy subjects, PR prolongation
was found independently correlated with endothelial
dysfunction and increased pulse-wave velocity even in
the absence of clinically manifest atherosclerotic disease
[6], suggesting that adverse vascular function could be
an intermediate pathological phenotype in subjects with
PR prolongation progressing towards clinical events. As
endothelial dysfunction indicates widespread functional
adversity of the CV system as a collective, it will be of
interest to dissect the role of PR prolongation in closely
related CV pathological entities commonly characterized
by abnormal vascular function, including myocardial in-
farction (MI) [7], ischemic stroke [8], and congestive heart
failure (CHF) [9].
Therefore, we investigated in this prospective cohort
study the role of PR prolongation as an independent
predictor in a continuum of pathophysiologically-linked
clinical events including ischemic stroke, MI, CHF, and
CV death in high-risk CV patients, and the relationships
between PR prolongation and indicator of abnormal vas-
cular function.
Methods
Study population, design and clinical assessments
We studied 597 consecutive patients with CAD or risk
equivalent recruited from outpatient medical specialty
clinics, as prior described [5]. Among them, 328 patients
had history of prior CAD (55%), 131 had ischemic stroke
(22%), and 310 had diabetes mellitus (52%). All patients
completed written informed consent. The study was ad-
herent to the Declaration of Helsinki and was approved
by the Ethics Committee, Hospital Authority (Hong
Kong West)/University of Hong Kong.
During the study period Dec 2007 to May 2012, occur-
rence of CV death, new-onset ischemic stroke,
MI and CHF were retrieved from the central computer-
ized clinical records archive of all public hospitals. Primary
endpoints of the study were carotid IMT and clinical
events of CV death, new-onset MI and ischemic stroke.
Secondary Endpoints were new-onset CHF and combined
CV endpoints, which included occurrences of any primary
endpoints or CHF. Baseline demographic, clinical and
laboratory assessments, clinical event definitions, and
the inclusion/exclusion criteria were prior detailed else-
where [5].
Carotid Intima–Media Thickness (IMT)
As previously described in details [10], carotid IMT was
assessed as the distance between lumen-intima and media-
adventitia borders of the carotid arterial wall using elec-
tronic calipers under high-resolution ultrasound. Three
measurements were taken at multiple sites on each side of
the carotid arteries with resultant averaged estimate incorp-
orating all measurements. Intraobserver variability analyses
revealed satisfactory correlation (R = 0.97, P < 0.001).
PR prolongation
Each participant had 12-lead ECG assessment after
rested in the supine position for 5 min. PR interval pro-
longation was defined as >200 ms [1]. An exploratory
cut-off of PR interval > 162 ms was further tested based
on the median cut-off correlated with endothelial dys-
function in our earlier exploratory study of 88 healthy
individuals [6]. Widened QRS duration was determined
as >120 ms [11].
Statistical analysis
Associations between PR interval and carotid IMT were
examined by univariable and multivariable linear regres-
sion. Kaplan-Meier analysis was used to assess differences
in survival as stratified by baseline PR interval status. A
multivariable Cox proportional regression model was used
to derive Hazard Ratios (HR) for incident CV events such
that potential confounder variables with p-value ≤0.20
(based on univariable analysis) were entered. Findings were
compared with aother Fully-Adjusted Model to verify
robustness of study findings, such that variables a priori
determined to be relevant were included (Additional file 1).
The Vascular Function Model further dissects effect of
carotid IMT adjustment in the estimates of PR interval as
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an independent predictor for CV events. SPSS Statistics
(Version 20) was used for the above analyses.
Results
Baseline clinical characteristics
As shown in Table 1, PR prolongation >200 ms was
present in 13% of patients (79/597). Patients with PR
prolongation had higher mean age (P < 0.001) and
greater male predominance (P < 0.001). There were no
significant differences in history of diabetes mellitus,
hyperlipidemia, smoking, physical activity, resting pulse
rate, systolic/diastolic blood pressure, fasting glucose,
HbA1c, and hsCRP (all P > 0.05). Lower LDL-cholesterol
was noted in patients with PR prolongation (P < 0.001)
with no differences in triglycerides and HDL-cholesterol
(P > 0.05), which could be partially due to higher preva-
lence of statin use among patients with PR prolongation,
albeit that was not statistically significant (P = 0.41). PR
prolongation was associated with higher serum creatinine
indicating impaired renal function (106.9 ± 59.6 versus
86.9 ± 29.2 mmol/L, P = 0.005), and a higher proportion
of patients with PR prolongation had prior CAD
(P = 0.037) or stroke (P = 0.017), with expectedly more
prevalent use of aspirin (P = 0.017) and ACEI/ARB
(P = 0.008). No between-groups difference of PR interval
were found regarding the use of nodal-blocking agents in-
cluding beta-blockers (use versus no use: 174.6 ± 27.1 ms
versus 171.2 ± 28.5 ms, P = 0.15; linear regression
(B = +3.3 [95% CI: -1.2 – 7.9], P = 0.39); and CCB (use
versus no use: 173.7 ± 26.5 ms versus 172.2 ± 28.3 ms,
P = 0.54; linear regression (B = +1.6 [95% CI: -3.5 – 6.6],
P = 0.54). QRS duration was similar between groups
(P = 0.14).
PR prolongation and adverse vascular function
In this group of high-risk patients with CAD or risk
equivalent, increased PR interval was positively associ-
ated with increased carotid IMT (Pearson R = 0.13,
P = 0.002). Patients with PR prolongation had signifi-
cantly higher mean carotid IMT (1.05 ± 0.37 versus
0.94 ± 0.28 mm, P = 0.010, Fig. 1). Adjusted for potential
confounding variables including age, gender, prior
stroke, smoking, body-mass index, resting pulse rate,
systolic blood pressure, hs-CRP, fasting glucose, creatin-
ine, and use of ACEI/ARB, CCB, beta-blockers, aspirin,
and widened QRS interval, PR prolongation >200 ms
remained independently associated with higher carotid
IMT by +0.073 mm (95% CI: 0.003–0.143, P = 0.041,
Additional file 1: Table S1). Repeated analysis by the
Fully-Adjusted model produced similar results (B = +0.074
[95% CI: 0.002–0.147], P = 0.044). Other positive predictors
for carotid IMT included age, prior stroke and systolic
blood pressure. Statin use was independently associated
with lower carotid IMT (P = 0.041). Diastolic blood pres-
sure was no longer a significant predictor after adjusting for
pulse pressure in relation to systolic blood pressure
(P > 0.05). QRS duration was not associated with carotid
IMT (R = 0.03, P = 0.55).
Prediction estimate of PR prolongation for new-onset
ischemic stroke and CV events
After mean study period of 63.4 ± 10.6 months, 21 (4%)
patients developed new-onset ischemic stroke; 26 (4%)
Table 1 Baseline characteristics of Participants by PR Interval
Status (n = 597)a
PR Interval
≤ 200 ms
(n = 518)
PR Interval
> 200 ms
(n = 79)
p-value
Male [n (%)] 334 (65%) 67 (85%) <0.001*
Age (years) 65.0 ± 11.1 70.5 ± 9.6 <0.001*
Body mass index (kgm−2) 25.2 ± 3.5 25.6 ± 3.2 0.34
Coronary Artery Disease [n (%)] 276 (53%) 52 (66%) 0.037*
Prior stroke [n (%)] 105 (21%) 26 (33%) 0.017*
Diabetes mellitus [n (%)] 274 (53%) 36 (46%) 0.23
Hypertension [n (%)] 330 (65%) 57 (72%) 0.20
Hyperlipidemia [n (%)] 320 (64%) 47 (60%) 0.48
Current/Past smoker [n (%)] 211 (42%) 43 (54%) 0.042
Regular Physical activity [n (%)] 185 (37%) 25 (12%) 0.40
Resting pulse rate (/min) 60.3 ± 21.2 63.7 ± 15.4 0.18
Systolic blood pressure (mmHg) 141.1 ± 20.5 140.2 ± 18.6 0.71
Diastolic blood pressure (mmHg) 79.0 ± 9.6 78.7 ± 9.3 0.83
LDL-cholesterol (mmol/L) 2.7 ± 0.7 2.4 ± 0.70 0.001*
HDL-cholesterol (mmol/L) 1.3 ± 0.3 1.2 ± 0.4 0.14
Tiglycerides (mmol/L) 1.5 ± 1.0 1.4 ± 0.7 0.37
Fasting glucose (mmol/L) 6.3 ± 2.1 6.1 ± 1.9 0.32
HbA1c (%) 7.0 ± 1.5 6.8 ± 1.2 0.22
hs-CRP (mg/L) 3.0 ± 8.9 2.7 ± 5.7 0.80
Serum creatinine (μmol/L) 86.9 ± 29.2 106.9 ± 59.6 0.005*
Medications:
ACEI/ARB [n (%)] 268 (54%) 55 (70%) 0.008*
Beta-blockers [n (%)] 241 (49%) 43 (54%) 0.39
Calcium channel blockers [n (%)] 140 (28%) 22 (28%) 0.97
Aspirin [n (%)] 323 (65%) 62 (79%) 0.017*
Statin [n (%)] 285 (57%) 49 (62%) 0.41
PR interval (ms) 164.7 ± 19.0 222.6 ± 22.0 <0.001*
QRS duration (ms) 94.3 ± 27.1 99.0 ± 17.8 0.14
Mean Carotid IMT (mm) 0.94 ± 0.28 1.05 ± 0.37 0.010*
HDL high-density lipoprotein, LDL low-density lipoprotein, HbA1c glycosylated
haemoglobin A1c, hs-CRP high-sensitivity C-reactive protein, ACEI angiotensin-
converting enzyme inhibitors, ARB angiotensin receptor blockers, IMT
intima-media thickness
*P-value < 0.05
aAll values are x ± SD, except where indicated otherwise
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patients developed new-onset MI; 37 (6%) patients de-
veloped new-onset CHF; 27 (5%) patients had CV death
and 87 (19%) patients developed any of these adverse CV
events as a combined endpoint (Table 2a and b). Patients
with PR prolongation >200 ms at baseline had significantly
higher risk of new-onset ischemic stroke (P = 0.006),
CHF (P = 0.039), CV death (P < 0.001), and combined
CV endpoint (P < 0.001). PR interval length was not as-
sociated with risk of new-onset MI at cut-off >200 ms
(P > 0.05) (primary cut-off ) but a positive association
was observed at the exploratory cut-off >162 ms
(P = 0.008). ROC Curve analysis revealed overall sig-
nificant prediction of PR interval for new-onset MI (C-
statistic 0.70, P = 0.001).
CV death
Incidence rates for CV death in patients with PR inter-
val ≤ 200 ms or >200 ms were respectively 0.6 and 1.8
per 100 person-years. Univariable analysis revealed that
age, resting pulse rate, systolic blood pressure, serum
hs-CRP, creatinine, widened QRS > 120 ms, and PR
prolongation were all significant positive predictors
for CV death (all P < 0.05). Furthermore, Kaplan-
Meier analysis showed that subjects with PR pro-
longation >200 ms had significantly reduced survival
(log rank: 14.4, P < 0.001, Fig. 2a). Multivariable Cox
regression analysis showed that adjusted for potential
confounders, PR prolongation >200 ms independently pre-
dicted substantially increased CV death (HR 6.53, 95% CI:
2.39–17.84, P < 0.001, Additional file 1: Table S2). Analyses
by the Fully-Adjusted Model yielded similarly robust esti-
mates (HR: 14.94, 95% CI: 3.99–55.92, P < 0.001). The
Fig. 1 PR Prolongation and Mean Carotid Intima-Media Thickness
(IMT). Patients with PR prolongation >200 ms had significantly higher
mean carotid IMT (1.05 ± 0.37 versus 0.94 ± 0.28 mm, P = 0.010)
Table 2 New-Onset Cardiovascular (CV) Events Stratified by Baseline PR Interval and QRS Duration
(a). PR interval
New-Onset CV Events n (%) Total (n = 597) PR Interval < 200 ms (n = 518) PR Interval > 200 ms (n = 79) P-value ROC C-Statistic
Estimate P-value
Myocardial infarction 26 (4%) 20 (4%) 6 (8%) 0.130 0.70 0.001*
Ischemic stroke 21 (4%) 14 (3%) 7 (9%) 0.006* 0.50 0.99
Congestive heart failure 37 (6%) 28 (5%) 9 (11%) 0.040* 0.60 0.042*
CV death 27 (5%) 17 (3%) 10 (13%) <0.001* 0.63 0.020*
Combined CV endpoints 87 (19%) 65 (13%) 22 (28%) <0.001* 0.61 0.001*
(b). QRS duration
New-Onset CV Events n (%) QRS Duration <120 ms (n = 556) QRS Duration >120 ms (n = 36) P-value ROC C-Statistic
Estimate P-value
Myocardial infarction - 22 (4%) 3 (8%) 0.21 0.55 0.37
Ischemic stroke - 20 (4%) 1 (3%) 0.80 0.47 0.60
Congestive heart failure - 30 (5%) 7 (19%) 0.001* 0.59 0.08
CV death - 24 (4%) 3 (8%) 0.26 0.62 0.03*
Combined CV endpoints - 76 (14%) 10 (28%) 0.020* 0.56 0.08
*P<0.05
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Vascular Function Model showed that adjusting for carotid
IMT did not materially alter the independent prediction by
PR prolongation (HR: 16.40, 3.99–67.46, P < 0.001). Other
independent positive predictors included HbA1c and hs-
CRP (both P < 0.05). Higher BMI was associated with re-
duced CV death (P < 0.05). On the other hand, PR interval
predicted total mortality with only marginal statistical sig-
nificance (C-statistic 0.58, P = 0.042), and that it did not
predict non-CV death (C-statistic 0.53, P = 0.63).
Ischemic stroke
Incidence rates for ischemic stroke in patients with PR
interval ≤ 200 ms or >200 ms were respectively 0.5 and
1.9 per 100 person-years. Age, serum creatinine, carotid
IMT, and PR prolongation >200 ms were all significant
predicting variables for new-onset ischemic stroke (all
P < 0.05). Furthermore, Kaplan-Meier analysis showed
that PR prolongation >200 ms was significantly associated
with reduced new-onset ischemic stroke-free survival (log
rank: 8.7, P = 0.003, Fig. 2b). By multivariable Cox regres-
sion, PR prolongation >200 ms independently predicted
increased risk of new-onset ischemic stroke (HR 3.76,
95% CI: 1.27–11.12, P = 0.016, Additional file 1: Table S3).
Analysis using the Fully-Adjusted Model gave similarly
robust estimates (HR: 5.36, 95% CI: 1.47–19.5, P = 0.011).
Adjusting for carotid IMT in the Vascular Function
Model, the independent predictive estimate by PR pro-
longation was only slightly attenuated (HR: 5.05, 95% CI:
1.34–19.10, P = 0.017).
MI
Incidence rates for MI in patients with PR interval ≤ 162 ms
or >162 ms were 0.3 and 1.3 per 100 person-years respect-
ively. Age, prior CAD, resting pulse rate, systolic blood
pressure, serum creatinine, history of ACEI/ARB use,
carotid IMT, and PR prolongation >162 ms (exploratory
cut-off) were all significant positive predictors for new-
onset MI (all P < 0.05). However, the primary cut-off of PR
interval > 200 ms was not associated with new-onset MI
(P = 0.11). Kaplan-Meier analysis showed that patients with
PR prolongation >162 ms had significantly reduced
new-onset MI-free survival (log rank: 7.4, P = 0.007,
Fig. 2c). Adjusting for potential confounders, PR pro-
longation >162 ms independently predicted increased
risk of new-onset MI (HR: 8.0, 95% CI: 1.65–38.85,
P = 0.010, Additional file 1: Table S4). Repeated analysis
using the Vascular Function Model did not materially
alter the independent prediction of new-onset MI by
PR prolongation >162 m (HR: 8.05, 95% CI: 1.66–39.06,
P = 0.010). Other independent positive predictors for
MI included age and prior CAD. BMI was associated
with reduced new-onset MI (P < 0.05).
Fig. 2 Kaplan-Meier Survival Curves for New-Onset Cardiovascular Events by PR Prolongation. Patients with PR prolongation >200 ms had significantly
reduced survival from a cardiovascular death (log rank: 14.4, P < 0.001); b Ischemic Stroke (log rank: 8.7, P = 0.003); d CHF (log rank: 5.0, P = 0.026) e
Combined Cardiovascular Endpoints (log rank: 14.2, P < 0.001). PR interval > 162 ms was associated with reduced survival from c new-onset MI (log
rank: 7.4, P = 0.007)
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CHF
Incidence rates for CHF in patients with PR interval ≤ 200ms
or >200 ms were 1.1 and 2.4 per 100 person-years re-
spectively. Age, resting pulse rate, systolic blood pres-
sure, physical inactivity, prior CAD, history of aspirin/
statin use, serum creatinine, hs-CRP, carotid IMT,
QRS > 120 ms, and PR prolongation >200 ms were
significant positive predictors of CHF (all P < 0.05).
Patients with PR prolongation >200 ms had signifi-
cantly reduced new-onset CHF-free survival (log rank:
5.0, P = 0.026, Fig. 2d). Nevertheless, after adjustment
for potential confounders, PR prolongation >200 ms
was no longer a significant predictor (HR: 1.29, 95% CI:
0.54–3.11, P = 0.56). Age, resting pulse rate, and history
of aspirin use remained independent predictors of CHF
(all P < 0.05).
Combined CV endpoints
Incidence rates for combined CV endpoints in patients
with PR interval ≤ 200 ms or >200 ms were 2.6 and 6.3
per 100 person-years respectively. Age, prior CAD,
smoking, systolic blood pressure, resting pulse rate, hs-
CRP, creatinine, history of ACEI/ARB use, QRS >120 ms,
carotid IMT, and PR prolongation >200 ms were all sig-
nificant positive predictors for increased combined CV
endpoints (all P < 0.05, Additional file 1: Table S5).
Kaplan-Meier analysis showed that patients with PR pro-
longation >200 ms had significantly reduced combined
endpoint-free survival (log rank: 14.2, P < 0.001, Fig. 2e).
Adjusted for potential confounders, PR prolongation
>200 ms remained an independent predictor for increased
combined CV endpoints (HR: 1.95, 95% CI: 1.11–3.43,
P = 0.020). The Fully-Adjusted Model yielded similar esti-
mates (HR: 2.40, 95% CI: 1.30–4.43, P = 0.005). Further
adjustment for carotid IMT did not materially alter the
independent prediction by PR prolongation (HR: 2.33,
95% CI: 1.26–4.32, P = 0.007). Other independent positive
predictors included age, prior CAD, hs-CRP and creatin-
ine (all P < 0.05).
Clinical utility in the prediction of CV events
The clinical utility measures of sensitivity, specificity,
positive predictive value (PPV) and negative predictive
value (NPV) at specific cut-off points of PR interval in
the prediction of each CV event were presented in
Additional file 1: Table S6.
Discussion
This is our first recognized study to show that PR pro-
longation alone is a strong and independent predictor
for CV death, new-onset ischemic stroke and MI, and
combined CV endpoints including CHF among patients
with CAD or risk equivalent. We also assessed the
vascular phenotype of these high-risk CV patients and
found that PR prolongation was independently related to
increased carotid IMT. Interestingly, despite the stated
observations, adjustment for carotid IMT did not materi-
ally alter the prediction of PR prolongation for incident
CV events, which suggests that atherosclerosis alone does
not fully explain the pathophysiological mechanism along
the pathway of PR prolongation leading to clinical events.
The clinical implications of this study are multi-fold.
Firstly, as opposed to the traditional school of thought
that considered PR prolongation as a benign ECG feature
[1], this study robustly showed that PR prolongation is
strongly predictive of a collective plethora of pathophysio-
logically related CV outcomes, including MI, ischemic
stroke, CHF and CV death. Recent epidemiological studies
(ARIC (2) and Framingham [3]) found higher risk of atrial
fibrillation associated with PR prolongation. Our findings
suggest that the pathophysiological implications of PR
prolongation is far more than atrial fibrillation, and entails
MI, ischemic stroke and CHF, all of which could be com-
monly characterized by impaired systemic vascular func-
tion [7–9]. PR prolongation alone, regardless of other
pertinent CV risk factors [12] such as those delineated in
the CHADS2 scores [5], is a simple and independent CV
risk predictor. Secondly, the magnitude of excess risk of
PR prolongation was substantial for various adverse out-
comes consistently (new-onset ischemic stroke: 4-fold
excess risk; new-onset MI, 7-fold excess risk; CV death:
15-fold excess risk), thus reflecting PR prolongation has
strong utility for CV prediction among high-risk patients.
Thirdly, while the recent Heart and Soul Study [4]
showed that PR prolongation predicted heart failure
hospitalization and CV death amongst patients with
stable CAD, our study further showed that PR pro-
longation has strong predictive applicability for CV
events in a much wider spectrum of high-risk patients
with prior CAD or other risk equivalents, including dia-
betes and stroke. Fourthly, the escalated risk of new-onset
MI emerged at a lower PR interval cut-off of >162 ms,
consistent with our prior exploratory study in terms of
subclinical changes in endothelial dysfunction [6], and
calls into question that early pathological changes may
well precede the conventional cut-off of PR prolongation
at >200 ms.
Mechanisms underlying our clinical observation are
likely multi-dimensional. Firstly, PR prolongation repre-
senting delayed atrioventricular conduction could be an
ECG manifestation of CV ageing [13]. Atherosclerosis is
increasingly recognized as a multi-factorial degenerative
disease that is closely related to the aging process. Our
analysis indicated that PR prolongation could be an
excellent clinical marker of CV ageing since adjustment
for chronological age did not obliterate the prediction of
carotid IMT and CV events by PR prolongation. Secondly,
myocardial fibrosis may involve the cardiac conduction
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system and is closely linked to the presence of CV risk
factors including CAD [14], hypertension [15], diabetes [16],
hyperlipidemia [17] and inflammation [18]. Thus PR pro-
longation may be a risk marker that reflects the clustering of
these important risk factors. Nevertheless, PR prolongation
may also reflect higher underlying vagal tone [19], especially
in the young [1], other than degenerative damage of the car-
diac conduction system which predominantly affects the
elderly [13]. In our study, comprehensive adjustment for im-
portant CV risk factors, even when including widened QRS
complex signifying overt ventricular electrical dyssynchrony
or widespread conduction system disease, did not abolish
PR prolongation as an independent CV predictor. Therefore
a third potential explanation arises: that PR prolongation
may be causal to adverse CV events. Indeed, PR prolonga-
tion, be it vagal- or degenerative-predominant, may mediate
its adverse vascular effects via increased intra-atrial pressure
consequential to slowed atrioventricular conduction,
resulting in neurohormonal activation [20]. Adverse
neurohormonal changes including raised aldosterone
may be reversible on sinus rhythm reversion [21]. Aldoster-
one is associated with a constellation of pro-atherosclerotic
changes including raised inflammatory response [22], re-
duced circulating endothelial progenitor cell quantity and
function [23] resulting in increased arterial stiffness [24].
Importantly, mineralocorticoid receptor blockade has been
shown clinically to improve atherosclerotic changes [25].
Indeed, if neurohormonal activation is the explanatory
mechanism that underlies PR prolongation-related vascular
dysfunction, such findings may translate into potentially im-
portant preventive implications through pharmacological
modulation of the neurohormonal system.
Vascular function as indicated by carotid IMT is a
strong, independent and consistent predictor of both in-
cident ischemic stroke and CV events overall among
healthy subjects from diverse ethnicities [26]. Increased
carotid IMT also predicts elevated risks of CV complica-
tions in patients with diabetes [27], hypertension [28]
and prior atherosclerotic diseases [29]. In this study, the
magnitude of increased carotid IMT by +0.07 mm
accounted for by PR prolongation is clinically significant,
since each 0.1 mm increase of carotid IMT could trans-
late into 18% excess risk of recurrent CV events [30].
On top of their greater susceptibility to CV events in
general, patients with prior CAD also have increased risk
of incident ischemic stroke, with diabetes being an add-
itional independent predictor [31, 32]. Our study further
suggests that the adverse prognostic value of PR pro-
longation is independent and over that of carotid IMT
for CV events in high-risk patients. Whether impaired
vascular function is indeed along the pathophysiological
pathway or simply a bystander will require further
mechanistic studies. Future studies could be strength-
ened by incorporating multiple vascular assessment
modalities to ensure consistent findings and scrutinise
further mechanisitc insights.
It should be noted that from our study, the magnitude of
risk associations of PR interval prolongation with new-onset
CV events was striking, and that IMT did not fully explain
such associations, suggesting that alternative mediating
pathophysiological mechanisms could be present. Also, the
HR estimates are relatively large. Despite our meticulous
efforts in the study design and data analysis to carefully
minimize biases or residual confounding, potential risk of
bias and confounding cannot be excluded totally. Findings
from the exploratory endpoint analyses should also best be
verified in another independent study. Furthermore, the
study of incident atrial fibrillation was not included in the
current study, which should be explored in the future.
Conclusions
In this prospective study of patients with CAD or risk-
equivalent, PR prolongation strongly and independently
predicts CV death, new-onset MI, ischemic stroke, and
combined CV endpoints including CHF. Increased risk
of MI emerged at a cut-off as low as PR interval > 162 ms.
Whether adverse vascular function in PR prolongation is
an intermediate phenotype or represent a mediating path-
way prior to clinical events warrants further investigations.
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